Sign up to save your podcasts
Or
Share COVID-19 response for Pharma with Vimal Narayanan - Conversations with Priya Ep #33 | Corporality
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
COVID-19 response for Pharma with Vimal Narayanan - Conversations with Priya Ep #33 | Corporality
#medtrix#pharmacompanies #bigpharma #healthcare #covid19 #secondwave #covidvaccine#newcovid
In this episode of 'Conversations with Priya', I talk to Vimal Narayanan - Founder and CEO of Medtrix Healthcare about Meditrix, according to their profile, seems to be more of a medical facilitator how their business works and what are the profit opportunities. He enlightens us on how the Pharmaceutical field is considered to be very rigid on the use of patents and licensing. How his company fit into the scenario and ensure that the rights of all stakeholders are protected. Mr Vimal shares his experience vis-a-vis companies after the COVID-19 epidemic and the changes associated with it.
Other topics include whether our CEO of Medtrix anticipates any major changes this year and what are the major sectors within the pharma sector that may see traction. Also, which geographies in your words are the best for your business and why?
View all episodes
By Corporality.Global
5
11 ratings
#medtrix#pharmacompanies #bigpharma #healthcare #covid19 #secondwave #covidvaccine#newcovid
In this episode of 'Conversations with Priya', I talk to Vimal Narayanan - Founder and CEO of Medtrix Healthcare about Meditrix, according to their profile, seems to be more of a medical facilitator how their business works and what are the profit opportunities. He enlightens us on how the Pharmaceutical field is considered to be very rigid on the use of patents and licensing. How his company fit into the scenario and ensure that the rights of all stakeholders are protected. Mr Vimal shares his experience vis-a-vis companies after the COVID-19 epidemic and the changes associated with it.
Other topics include whether our CEO of Medtrix anticipates any major changes this year and what are the major sectors within the pharma sector that may see traction. Also, which geographies in your words are the best for your business and why?